Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
It is a non-randomized pilot study.The allocation will be determined by patients or their
immediate family members who were cooperative with physician's interpretations on the disease
progression and updated information of cutting of edge treatment, the financial
affordability, availability of treatment plans, possible tolerance or risks etc.The purpose
of this study is to investigate the clinical efficacy and toxicity of autologous cellular
immunotherapy combined with hyperthermia in abdominal and pelvic malignancies or metastases
patients. Furthermore, to characterize response to different regimens,the investigators
intent to explore the predictive and prognostic biomarker, as well as the changes in immune
repertoire.